Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320381 | 0.83 | NAMPT (1.00) | NAMPTTSHRMAPK1RAB9AALDH1A1 | |
| SCHEMBL23320431 | 0.78 | NAMPT (0.75) | NAMPTRAB9AALDH1A1NPC1 | |
| SCHEMBL30943187 | 0.78 | NAMPT (0.75) | NAMPTRAB9AALDH1A1NPC1 | |
| SCHEMBL23320437 | 0.77 | NAMPT (0.65) | NAMPTRAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL23320408 | 0.75 | NAMPT (0.84) | NAMPTTSHRMAPK1RAB9AALDH1A1 | |
| SCHEMBL27157147 | 0.74 | FGFR1 (0.43) | NAMPT | |
| SCHEMBL23320402 | 0.74 | NAMPT (0.81) | NAMPTTSHRMAPK1RAB9AALDH1A1 | |
| SCHEMBL23320538 | 0.73 | FGFR1 (0.41) | NAMPT | |
| SCHEMBL20379624 | 0.70 | NAMPT (1.00) | NAMPT | |
| SCHEMBL23019288 | 0.70 | ROCK2 (0.63) | NAMPTTSHRAURKBMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | claimed |
| CN-112654608-B | Fused ring compound having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2024-05-07 | — | — | CN | disclosed |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | NAMPT 1/4885TSHR 2060/4885AURKB 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.